Premium
Survivin Signaling in Clinical Oncology: A Multifaceted Dragon
Author(s) -
Kanwar Jagat R.,
Kamalapuram Sishir K.,
Kanwar Rupinder K.
Publication year - 2013
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21264
Subject(s) - survivin , cancer research , mapk/erk pathway , kinase , epidermal growth factor receptor , stat protein , protein kinase b , signal transduction , biology , cell growth , cancer , medicine , stat3 , microbiology and biotechnology , genetics
Survivin is an inhibitor of apoptosis protein ( IAP ) family member preferentially expressed in a myriad of clinical cancers. The complex functional mechanism and regulatory roles of survivin in cell division and cell death has hindered current therapeutic regimes from decoding its diagnostic, prognostic, and therapeutic significance in the area of translational oncology. Pharmacological modulation of survivin was tagged with its evolving functional complexity associated with various cell‐signaling cascades including P I3 K / AKT , mammalian target of rapamycin (m TOR ), extracellular signal‐regulated kinases ( ERK ), mitogen‐activated protein kinases ( MAPK ), signal transducer and activator of transcription ( STAT ), hypoxia‐inducible factor‐1α ( HIF ‐1α), heat‐shock protein 90 ( HSP 90), p53, B‐cell lymphoma 2 ( B cl2), epidermal growth factor receptor ( EGFR ), vascular endothelial growth factor ( VEGF ) etc. The present review provides a multifaceted role of survivin and its mechanistic action in an array of clinical cancers. Furthermore, the utilization of novel nanotechnology‐based drug delivery systems for target‐specific hurling of tumors enabling contemporaneous detection, treatment, and therapeutic imaging in cancer therapy are discussed.